Clinical trial
A Prospective, Multicentric, Proof-of-concept Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
NCT05268952 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicentric, Proof-of-concept Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
- Lead sponsor
- University Hospital, Antwerp
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- May 27, 2019
- Completion date
- December 31, 2025
- Enrollment
- 100 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.